| 产品编号 | D51753 |
| 英文名称 | Baricitinib |
| 中文名称 | |
| 别 名 | JAK1/JAK2 抑制剂 |
| 产品介绍 |
Baricitinib, also known as INCB028050 or LY3009104, is a selective orally bioavailable JAK1/JAK2 inhibitor with nanomolar potency against JAK1 (5.9 nM) and JAK2 (5.7 nM). INCB028050 inhibits intracellular signaling of multiple proinflammatory cytokines including IL-6 and IL-23 at concentrations <50 nM. INCB028050 was also effective in multiple murine models of arthritis, with no evidence of suppression of humoral immunity or adverse hematologic effects. Baricitinib was approved for the treatment of rheumatoid arthritis (RA) in the United States. CAS号：1187594-09-7 分子式：C16H17N7O2S 分子量：371.42 MDL：MFCD27920779 级别：AR 纯度：98% 外观/性状：类白色或白色结晶性粉末，无臭无味。 溶解性：在水中略溶，在热水中溶解，在乙醇或丙酮中不溶，在氢氧化钠试液中易溶。 敏感性：吸湿性 作用靶点：JAK; 作用通路：Epigenetics; JAK/STAT Signaling; Stem Cell/Wnt; 描述：巴瑞克替尼 (Baricitinib) 是选择性，可口服的 JAK1 和 JAK2 |
| 1、抗体溶解方法 | |
| 2、抗体修复方式 | |
| 3、常用试剂的配制 | |
| 4、免疫组化操作步骤 | |
| 5、免疫组化问题解答 | |
| 6、Western Blotting 操作步骤 | |
| 7、Western Blotting 问题解答 | |
| 8、关于肽链的设计 | |
| 9、多肽的溶解与保存 | |
| 10、酶标抗体效价测定程序 | |
